[A17-56] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 05.04.2018
Commission awarded on 16.10.2017 by the Federal Joint Committee (G-BA).
Adult patients with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy
Advantage in overall survival and disadvantages regarding side effects; overall indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2018-04-05 A G-BA decision was published.